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A B S T R A C T
Background
Bronchiectasis is being increasingly diagnosed and recognised as an important contributor to chronic lung disease in both adults and
children in high- and low-income countries. It is characterised by irreversible dilatation of airways and is generally associated with airway
inflammation and chronic bacterial infection. Medical management largely aims to reduce morbidity by controlling the symptoms,
reduce exacerbation frequency, improve quality of life and prevent the progression of bronchiectasis. This is an update of a review first
published in 2000.
Objectives
To evaluate the efficacy and safety of inhaled corticosteroids (ICS) in children and adults with stable state bronchiectasis, specifically
to assess whether the use of ICS: (1) reduces the severity and frequency of acute respiratory exacerbations; or (2) affects long-term
pulmonary function decline.
Search methods
We searched the Cochrane Register of Controlled Trials (CENTRAL), the Cochrane Airways Group Register of trials, MEDLINE and
Embase databases. We ran the latest literature search in June 2017.
Selection criteria
All randomised controlled trials (RCTs) comparing ICS with a placebo or no medication. We included children and adults with clinical
or radiographic evidence of bronchiectasis, but excluded people with cystic fibrosis.
Data collection and analysis
We reviewed search results against predetermined criteria for inclusion. In this update, two independent review authors assessed
methodological quality and risk of bias in trials using established criteria and extracted data using standard pro forma. We analysed
treatment as ’treatment received’ and performed sensitivity analyses.
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Main results
The review included seven studies, involving 380 adults. Of the 380 randomised participants, 348 completed the studies.
Due to differences in outcomes reported among the seven studies, we could only perform limited meta-analysis for both the short-term
ICS use (6 months or less) and the longer-term ICS use (> 6 months).
During stable state in the short-term group (ICS for 6 months or less), based on the two studies from which data could be included,
there were no significant differences from baseline values in the forced expiratory volume in the first second (FEV1) at the end of the
study (mean difference (MD) -0.09, 95% confidence interval (CI) -0.26 to 0.09) and forced vital capacity (FVC) (MD 0.01 L, 95% CI
-0.16 to 0.17) in adults on ICS (compared to no ICS). Similarly, we did not find any significant difference in the average exacerbation
frequency (MD 0.09, 95% CI -0.61 to 0.79) or health-related quality of life (HRQoL) total scores in adults on ICS when compared
with no ICS, though data available were limited. Based on a single non-placebo controlled study from which we could not extract
clinical data, there was marginal, though statistically significant improvement in sputum volume and dyspnoea scores on ICS.
The single study on long-term outcomes (over 6 months) that examined lung function and other clinical outcomes, showed no
significant effect of ICS on any of the outcomes. We could not draw any conclusion on adverse effects due to limited available data.
Despite the authors of all seven studies stating they were double-blind, we judged one study (in the short duration ICS) as having a
high risk of bias based on blinding, attrition and reporting of outcomes. The GRADE quality of evidence was low for all outcomes
(due to non-placebo controlled trial, indirectness and imprecision with small numbers of participants and studies).
Authors’ conclusions
This updated review indicates that there is insufficient evidence to support the routine use of ICS in adultswith stable state bronchiectasis.
Further, we cannot draw any conclusion for the use of ICS in adults during an acute exacerbation or in children (for any state), as there
were no studies.
P L A I N L A N G U A G E S U M M A R Y
Role of inhaled corticosteroids (ICS) in the management of bronchiectasis
Background
Bronchiectasis is a lung disease. People with bronchiectasis often experience long-term symptoms such as productive or wet cough,
repeated flare-ups (exacerbations) and poor quality of life. People with bronchiectasis have airway inflammation and many have asthma-
like symptoms (such as cough and wheeze). Because of this, inhaled corticosteroids (ICS), commonly used in asthma, might also
improve symptoms, reduce flare-ups and/or reduce worsening of lung function for people with bronchiectasis. However, routine use
of ICS may also cause unwanted side effects.
Review question
What are the benefits of using ICS regularly in the management of adults and children with bronchiectasis?
Study characteristics
We included studies that compared ICS with no ICS, or with a placebo (i.e. a medication made to look the same as ICS but with
no active ingredients). We only included studies where it was decided at random who would receive ICS and who would not. The
participants included in the seven studies were 380 adults who had bronchiectasis diagnosed by symptoms or from a detailed lung
scan (computed tomography (CT)). We did not include studies that involved participants with cystic fibrosis, which can also cause
bronchiectasis. Although we planned to include studies involving children with bronchiectasis, we did not find such studies.
What evidence did we find?
From available evidence up to June 2017, we found seven eligible studies involving adult participants that examined the role of ICS in
bronchiectasis. The adults had stable bronchiectasis - they were not having a flare-up at the start of the study.
We were able to include results from two studies that gave ICS for less than six months to adults with stable bronchiectasis. ICS did
not make a difference to lung function, number of exacerbations during the study or quality of life. In a different study, which also
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gave ICS for less than six months, we found a small reduction in sputum (phlegm) and improvement in breathlessness. However, as
these results were from a study which did not use a placebo we cannot be certain about them.
The single study on long-term use of ICS (i.e. for over 6 months) showed no meaningful benefit of ICS for any of the outcomes.
There were no studies conducted when the participants were having a flare-up of their bronchiectasis. There were also no studies that
involved children with bronchiectasis. Importantly, we do not know if ICS are linked to more unwanted side effects, because the studies
did not provide much information about this.
Conclusion
The review found that there is not enough evidence for the routine use of ICS in adults with stable bronchiectasis. We can make no
conclusions about the use of ICS for flare-ups of bronchiectasis, or about their use in children, because we did not find any studies.
Quality of evidence
Overall, we judged the quality of evidence to be low. We were concerned because the largest study, which showed some benefits, did
not use a placebo. This means that participants and staff in the study would have known who was getting ICS and who was not, which
could affect the results. Also, our confidence was reduced because we only found a small number of studies to include in our review
and some of the studies may have included people with other types of lung disease, in addition to bronchiectasis.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Inhaled corticosteroids compared to placebo for bronchiectasis (< 6 months)
Patient or population: people with bronchiectasis
Setting: university hospital
Intervention: inhaled cort icosteroids
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with Inhaled corti-
costeroids
Lung funct ion (spirom-
etry indices) -FEV1 (in L,
end study minus base-
line values)
Mean change f rom
baseline ranged f rom -
0.038 to 0.805
MD 0.09 lower
(0.26 lower to 0.09
higher)
- 156
(2 studies)
⊕⊕©©
Low1,2,3
Lung funct ion (spirom-
etry indices) - FVC (in L,
end study minus base-
line values)
Mean change f rom
baseline ranged f rom -
0.062 to 0.0218
MD 0.01 higher
(0.16 lower to 0.17
higher)
- 156
(2 studies)
⊕⊕©©
Low1,2,3
Lung funct ion (other in-
dices) - dif f usion ca-
pacity % predicted (end
of study)
Mean end of study
value 84.2
MD 2.70 higher
(2.49 lower to 7.89
higher)
- 57
(1 study)
⊕⊕©©
Low1,2,3
Lung funct ion (other in-
dices) - RV % predicted
(end of study values)
Mean end of study
value 106
MD 2.00 higher
(9.41 lower to 13.41
higher)
- 57
(1 study)
⊕⊕©©
Low1,2,3
Lung funct ion (other in-
dices) - TLC%predicted
(end of study values)
Mean end of study
value 86.4
MD 3.20 higher
(1.99 lower to 8.39
higher)
- 57
(1 study)
⊕⊕©©
Low1,2,3
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Average number of ex-
acerbat ions per part ici-
pant
Average number of ex-
acerbat ions per pat ient
ranged f rom 0.97 to 1.
31
MD 0.17 lower
(0.56 lower to 0.22
higher)
- 127
(2 studies)
⊕⊕©©
Low1,2,3
Pseudomonas aeruginosa
(P aeruginosa) colonisa-
t ion
410 per 1000 395 per 1000
(238 to 576)
OR 0.94
(0.45 to 1.96)
156
(2 studies)
⊕⊕©©
Low1,2,3
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; FEV1: f orced expiratory volume in 1 second; FVC: f orced vital capacity; MD: mean dif ference; OR: odds rat io; RV: residual volume; TLC: total lung
capacity
GRADE Working Group grades of evidence
High-certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate-certainty: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low-certainty: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low-certainty: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1The largest study was not a placebo controlled trial (Mart inez-Garcia 2006).
2Study part icipant numbers are small; outcome downgraded one point for imprecision.
3One study had an issue with directness (Joshi 2004), but did not contribute to this outcome.
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B A C K G R O U N D
Description of the condition
Bronchiectasis, previously termed an ’orphan disease’ is increas-
ingly recognised as a major cause of respiratory morbidity, espe-
cially in low-income countries (Karadag 2005; Karakoc 2001),
and in some ethnic populations of affluent countries (Chang
2002; Edwards 2003; Singleton 2000). More recently, it has
also been increasingly reported from some high-income countries
(Sanchez-Munoz 2016). Bronchiectasis is the end result of a vari-
ety of airway insults and predisposing conditions that culminate in
airway injury, recurrent or persistent airway infection and destruc-
tion (Chang 2010). The underlying aetiology of bronchiectasis
varies from being a consequence of recurrent respiratory infections
to rare immune deficiencies. Other causes include primary ciliary
dyskinesia, allergic bronchopulmonary aspergillosis and mycobac-
terial infection (Olveira 2017; Shoemark 2007). A common fea-
ture of most patients is the impaired local and/or systemic host
defences to infection.
The dominant symptoms and signs of bronchiectasis are produc-
tive or wet cough, dyspnoea on exertion and presence of other res-
piratory signs (clubbing, chest wall deformity, respiratory noises
such as wheeze or crepitations on auscultation). In the long-
term, pulmonary function decline may occur (Keistinen 1997;
Twiss 2006). In studies involving both children and adult cohorts,
asthma-like symptoms in people with bronchiectasis have been
described and when present, are associated with accelerated pul-
monary function decline when compared to those with bronchiec-
tasis, but without asthma-like symptoms (Field 1969; Keistinen
1997).
Like people with chronic obstructive pulmonary disease (COPD)
and cystic fibrosis, children and adults with bronchiectasis also
suffer from recurrent acute exacerbations, some of whom require
hospitalised treatment. Pulmonary exacerbations present with a
worsening of the baseline clinical state (Kapur 2012a), and are
associated with increased morbidity (Kapur 2009), progressive de-
terioration in lung function (Ellerman 1997; Kapur 2010), and
poor quality of life in both adults and children with bronchiec-
tasis (Kapur 2012; Wilson 1997). Effective management regimes
for bronchiectasis would reduce the frequency or severity of res-
piratory exacerbations, and/or the long-term pulmonary function
decline.
The hallmarks of bronchiectasis are stasis of infected airway secre-
tions; reduced airway mucus clearance; and regional or diffuse air-
way wall dilatation, thickening and destruction with loss of airway
structural integrity (Mandal 2013). Based on Cole’s ’vicious circle
hypothesis’, microbial colonisation/infection is important in the
pathophysiology of bronchiectasis, as it leads to bronchial obstruc-
tion and a normal or exaggerated inflammatory response (Cole
1986). As in COPD, chronic airway obstruction and bronchial
hyper-responsiveness is known to occur in bronchiectasis. A vari-
ety of proinflammatory airway cells such as neutrophils, lympho-
cytes, macrophages and eosinophils have been implicated in the
pathogenesis of both bronchiectasis and COPD (Mandal 2013;
Kim 2008).
Although inflammation is considered an important driver of
bronchial hyper-responsiveness and airway instability in air-
way diseases such as COPD and asthma (Berend 2008), evi-
dence directly implicating it in bronchial hyper-responsiveness in
bronchiectasis is unclear. Since bronchiectasis involves similar air-
way inflammatory mediators, suppression of this inflammatory
process could potentially slow the rate of airway damage.
Description of the intervention
The anti-inflammatory effect of corticosteroids on the airways
has been well documented in inflammatory airway diseases, such
as asthma (Booth 1995), and COPD (Renkema 1996; Sobieraj
2008). Inhaled preparation of corticosteroids provide a non-spe-
cific, local anti-inflammatory effect with minimal systemic side
effects. ICS are available as metered dose inhalers, dry powder
devices or nebulised, and can be used for short or long dura-
tions. Short duration use of ICS likely has different effects com-
pared to longer-term ICS use for our primary outcome of inter-
est (lung function), as well as for other adverse event outcomes,
such as bone metabolism (Kerstjens 1994), and children’s growth
(Pruteanu 2014), further discussed in the last paragraph of the
’Data synthesis’ section.
Inhaled corticosteroids (ICS) are beneficial in some (but not all)
people with COPD (Ernst 2015). However, use of ICS is associ-
ated with adverse events in children and adults that range from
mild (candidiasis) to serious (adrenal insufficiency (Holme 2008),
osteoporosis, cataracts, pneumonia) events. Recent evidence in-
dicates increased risk of pneumonia and lower respiratory tract
infections with use of ICS in adults with COPD (Wang 2016).
Since bronchiectasis involves similar disruption of the host airway
defences, it is plausible that this cohort is also at higher risk of
respiratory infections with the use of ICS.
How the intervention might work
Airway eosinophilia and bronchial hyper-responsiveness has been
reported in adults (Ip 1991; Tsikrika 2017), and children with
bronchiectasis (Goyal 2016; Pizzutto 2013), hence ICS may be
potentially beneficial for this group of patients, as ICS is usually
efficacious in people with airway eosinophilia.
Why it is important to do this review
The role of ICS in bronchiectasis remains unclear. An update
of the original systematic review on the efficacy of ICS in the
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management of children and adults with bronchiectasis (Kapur
2009) could help guide clinical practice.
O B J E C T I V E S
To evaluate the efficacy and safety of inhaled corticosteroids (ICS)
in children and adults with stable state bronchiectasis, specifically
to assess whether the use of ICS: (1) reduces the severity and
frequency of acute respiratory exacerbations; or (2) affects long-
term pulmonary function decline.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) using inhaled corticos-
teroids (ICS) in patients with bronchiectasis, in comparison to
placebo.
Types of participants
Children or adults with bronchiectasis (defined clinically or radi-
ologically) not related to cystic fibrosis.
Types of interventions
All types of ICS.
Types of outcome measures
Primary outcomes
1. Change in objective measures of lung function.
Secondary outcomes
(A) for short-term effectiveness (6 months or less)
1. Mean difference in bronchiectasis severity control (wheeze,
dyspnoea, cough diary, etc).
2. Mean of respiratory exacerbations, or hospitalisations per
participant, or both.
3. Sputum volume.
4. Mean difference in other objective indices (airway markers
of inflammation, exhaled nitric oxide, etc).
5. Mean difference in quality of life indices.
6. Proportions experiencing adverse effects of the intervention,
(e.g. pharyngeal candidiasis, voice change, pneumonia, etc).
(B) for medium- to long-term outcomes (greater than 6
months)
1. Clinical indices of bronchiectasis severity control (quality of
life, cough diary, Likert scale, visual analogue scale, level of
interference of cough, etc).
2. Relevant airway markers of inflammation.
3. Proportions experiencing adverse effects of the intervention,
(e.g. adrenal insufficiency, cataracts, linear growth, etc).
4. Frequency of exacerbation per subject.
Search methods for identification of studies
Electronic searches
This is an update of a previous Cochrane Review (Kapur 2009).
For this update, we identified studies from the following sources.
1. The Cochrane Airways Group Trials Register (updated June
2017).
2. The Cochrane Central Register of Controlled Trials
(CENTRAL; Issue 5, 2016.
3. MEDLINE (1950 to June 2017).
4. Embase (1980 to June 2017).
5. The list of references in relevant publications.
6. Written communication with the study authors of the
studies included in the review, when necessary.
For the full database topic search strategies, see Appendix 1. We
searched all databases with no restriction on language of publi-
cation. We searched the CENTRAL database for handsearched
conference abstracts and grey literature.
We also conducted searches of Clini-
calTrials.gov (www.ClinicalTrials.gov), and theWorld Health Or-
ganization (WHO) trials portal (www.who.int/ictrp/en/), using
the search strategy in Appendix 2. We searched all databases from
their inception to 5 February 2018, and we imposed no restriction
on language of publication.
Searching other resources
We wrote to the lead authors of all the studies included and three
study authors replied; we incorporated any information provided.
Data collection and analysis
Selection of studies
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From the title, abstract, or descriptors, two review authors (NK,
AC) independently reviewed the literature searches to identify po-
tentially relevant studies for full review. There was no disagree-
ment between the review authors as to which studies should be
included. We recorded the selection process in sufficient detail to
complete the PRISMA (PRISMA 2009) flow diagram (Figure 1)
and Characteristics of excluded studies table.
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Figure 1. Study flow diagram.
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Data extraction and management
We reviewed studies that satisfied the inclusion criteria and
recorded the following information: study setting, year of study,
source of funding, participant recruitment details (including num-
ber of eligible participants), inclusion and exclusion criteria, other
symptoms, randomisation and allocation concealment method,
numbers of participants randomised, blinding (masking) of par-
ticipants, care providers and outcome assessors, dose and type of
intervention, duration of therapy, cointerventions, numbers of
participants not followed up, reasons for withdrawals from study
protocol (clinical, side effects, refusal and other), details on side
effects of therapy, and whether intention-to-treat analyses were
possible. We extracted data independently on the outcomes de-
scribed previously. We requested further information from the
study authors, but only three responded (Hernando 2012; Joshi
2004; Martinez-Garcia 2006); we incorporated the information
received.
Assessment of risk of bias in included studies
We included all assessments in the ’Characteristics of included
studies’ table. We measured inter-reviewer reliability for the iden-
tification of high quality studies for each component using the
Kappa statistic. Agreement between the two review authors was
excellent (weighted kappa score for quality assessment scores was
0.81).
Two review authors (NK, AC) independently assessed risk of bias
for each study using the criteria outlined in theCochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).We resolved
disagreement by discussion. We assessed the risk of bias according
to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low or unclear
and provided a quote from the study report together with a jus-
tification in the ’Risk of bias’ table. We summarised the ’Risk of
bias’ judgements across different studies for each of the domains
listed. We carried out blinding separately for different key out-
comes, where necessary. Where information on risk of bias related
to unpublished data or correspondence with a trialist, we noted
this in the ’Risk of bias’ table.
When considering treatment effects, we took into account the risk
of bias for the studies that contributed to that outcome.
Measures of treatment effect
The statistical analysis proposed, included calculation of a pooled
estimate of treatment effect for each dichotomous outcome across
all studies (odds of outcome in participants allocated to receive
treatment compared with odds of outcome in participants allo-
cated to control group); and calculation of a pooled estimate of
treatment effect for each continuous outcome across all studies in
the form of a mean difference (MD). For continuous variables, we
recorded mean absolute change from baseline for each group and
standard deviation (SD) for each group.
Unit of analysis issues
We used the participant as the unit of analysis.
Dealing with missing data
We sought data on a number of participants with each outcome
event listed above, by allocated treatment group in order for us to
conduct an intention-to-treat (ITT) analysis. We also contacted
the study investigators for clarification and further information
where necessary.
Assessment of heterogeneity
We described and tested any heterogeneity between the study re-
sults to see if it reached statistical significance using a chi2 test.
We estimated the 95% confidence interval (CI) using a random-
effects model whenever there were concerns about statistical het-
erogeneity.
Assessment of reporting biases
We checked all reports of the included studies to check that all the
stated outcomes were reported and the results were presented in
the ’Risk of bias table’ in the ’Characteristics of included studies’
table.
Data synthesis
We calculated odds ratio (OR) using a modified ITT analysis for
the dichotomous outcome variables of each individual study. This
analysis assumes that participants not available for outcome as-
sessment have not improved (and probably represents a conserva-
tive estimate of effect). An initial qualitative comparison of all the
individually analysed studies examined whether pooling of results
(meta-analysis) is reasonable. This took into account differences
in study populations, inclusion/exclusion criteria, interventions,
outcome assessment, and estimated effect size.
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We included results from studies thatmet the inclusion criteria and
reported any of the outcomes of interest in the subsequent meta-
analyses. We calculated the summary weighted risk ratio (RR) and
95% CI (fixed-effect model) using Review Manager 5 (Review
Manager 2014). For cross-over studies, we calculated mean treat-
ment differences from raw data. We extracted or imputed and
entered the date as fixed-effect generic inverse variance outcomes
to provide summary weighted differences and 95% CIs. In cross-
over trials, we only included data from the first arm in meta-anal-
ysis when the data were combined with parallel studies (Elbourne
2002). We calculated numbers needed to treat to benefit (NNTB)
were calculated from the pooled OR and applied its 95% CI to a
specified baseline risk using an online calculator (Cates 2008). If
studies had reported outcomes using differentmeasurement scales,
we planned to use the standardised mean difference (SMD).
’Summary of findings’ table
We created ’Summary of findings’ tables using the following out-
comes.
Short-term ICS use (≤ 6 months)
• Lung function indices forced expiratory volume in the first
second (FEV1) and forced vital capacity (FVC) (in L, end of
study minus baseline values)
• Lung function indices diffusion capacity % predicted (end
of study values)
• Average number of exacerbations per participant
• Pseudomonas aeruginosa (P aeruginosa) colonisation
There are various types of lung function abnormality in people
with bronchiectasis (Guan 2014). As this was our primary out-
come measure, we included the various indices that reflect these
abnormalities.
Longer-term ICS use (> 6 months)
• Lung function indices FEV1 and FVC (in L, end of study
minus baseline values)
• Average number of exacerbations per participant
We used the five GRADE considerations (study limitations, con-
sistency of effect, imprecision, indirectness, and publication bias)
to assess the quality of a body of evidence as it relates to the studies
that contributed data to themeta-analyses for the prespecified out-
comes. We then used methods and recommendations described
in Section 8.5 and Chapter 12 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011), using GRADEpro
software (GRADEpro GDT 2015). We justified all decisions to
downgrade the quality of studies using footnotes, and we made
comments to aid the reader’s understanding of the review where
necessary.
We evaluated the outcomes described above based on short (6
months or less) and long duration (> 6 months) use of ICS, as
done previously in our Cochrane Review (Kapur 2009). This ar-
bitrary cut-off is a commonly used time frame in studies (Daniel
2017; Kerstjens 1994; Lee 2012), when evaluating the effects
of ICS, as duration of ICS use may impact on clinical and
structural pulmonary outcomes (e.g. airway remodelling (Barnes
2010)), and adverse events (e.g. growth (Pruteanu 2014)), and
bone metabolism (Kerstjens 1994). Lung function in people with
bronchiectasis generally declines slowly over time and as this was
our a priori defined primary outcome, the effect of short dura-
tion ICS theoretically could differ from longer duration ICS.Out-
comes such as bronchial hyper-responsiveness takesmonths of ICS
therapy to plateau (Barnes 2010). An example with respect to ad-
verse events: in theCochrane Review on the effect of ICS on height
in growing children with asthma, the authors found no difference
between groups (ICS versus placebo) in the first six months of
ICS use, but a significant difference between groups was present
in ICS use at the 12 months time point (Pruteanu 2014).
Subgroup analysis and investigation of heterogeneity
We planned the following a priori subgroup analysis.
1. Children (aged 18 years or less) and adults (> 18 years).
2. Dose of ICS; low (< 400 µg), moderate (400 µg to 800 µg),
high (> 800 µg) of beclomethasone equivalent.
3. Severity of bronchiectasis (based on lung function).
Sensitivity analysis
We also planned sensitivity analyses to assess the impact of the
following potentially important factors on the overall outcomes.
1. Study quality.
2. Variation in the inclusion criteria.
3. Differences in the medications used in the intervention and
comparison groups.
4. Analysis using random-effects model.
5. Analysis by ’treatment received’.
R E S U L T S
Description of studies
Results of the search
For the updated review in 2009 the AirwaysGroupRegister identi-
fied 341 potentially relevant titles. After assessing the abstracts, we
obtained nine papers for consideration for inclusion in the review.
We excluded three studies as inhaled corticosteroids (ICS) were
not compared to placebo/no treatment or were non-randomised
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studies or included participants with pneumonia (Ghosh 2002;
Monton 1999;ONeil 2004; see Characteristics of excluded studies
table).
For this 2018 update, we conducted searches from 2011 to 30
June 2017 and the Cochrane Airways Group’s Register identi-
fied 111 new references; we identified an additional 277 titles
through searches of ClinicalTrials.gov (www.ClinicalTrials.gov),
and the WHO trials portal (www.who.int/ictrp/en/). After as-
sessing the abstracts, we obtained three articles for consideration
to be included in the review; we excluded two studies because
ICS was compared to an ICS-long-acting beta2-agonist (LABA)
combination (Martinez-Garcia 2012), or was a non-randomised
study (Guran 2008). We included one new study in this update
(Hernando 2012) (Figure 1).
Included studies
See Characteristics of included studies and Table 1 ’Summary of
included studies characteristics’.
We identified one new study for this review update (Hernando
2012), including 77 participants. A total of seven studies met the
inclusion criteria for this review update (Elborn 1992; Hernando
2012; Joshi 2004; Martinez-Garcia 2006; Tsang 1998; Tsang
2004; Tsang 2005). All included studies identified were published
in English. We requested additional data from all study authors
but only three authors responded (Hernando 2012; Joshi 2004;
Martinez-Garcia 2006), and provided additional data. We also
requested data on outcomes at 24 weeks for the Tsang 2005 study
as well as the lung function values in actual volumes (instead of
percentage predicted) from the study authors.
Study design and population
All seven studies were single centre studies. The studies included
participants with bronchiectasis diagnosed on bronchography
(Elborn 1992), or high resolution computed tomography (HRCT)
of the chest (Hernando 2012; Joshi 2004; Martinez-Garcia 2006;
Tsang 1998; Tsang 2004; Tsang 2005). All studies excluded par-
ticipants with cystic fibrosis, with six studies excluding partici-
pants with bronchial asthma also (Hernando 2012; Joshi 2004;
Martinez-Garcia 2006; Tsang 1998; Tsang 2004; Tsang 2005).
Participants with allergic bronchopulmonary aspergillosis were
also excluded from theElborn1992 study and theMartinez-Garcia
2006 study. None of the studies included any children.
The Joshi 2004 and Elborn 1992 studies were cross-over studies
and the others were parallel group studies. All were double-blind
placebo controlled trials except the Martinez-Garcia 2006 study,
which did not use placebo in the control group.
Participants with bronchiectasis were recruited during stable state,
defined as “free from exacerbation for four weeks” (Hernando
2012; Joshi 2004;Martinez-Garcia 2006), or “stable 24-hour spu-
tum volume, FEV1 and FVC” (Tsang 1998; Tsang 2004; Tsang
2005). No study was performed during an acute respiratory exac-
erbation.
Interventions
Moderate to high doses of ICS were used: budesonide 800 µg/
day (Hernando 2012), beclomethasone 800 µg/day (Joshi 2004),
beclomethasone 1500 µg/day in the Elborn 1992 study and
fluticasone 1000 µg/day (2000 µg/day budesonide equivalent)
(Martinez-Garcia 2006; Tsang 1998; Tsang 2004; Tsang 2005).
The Martinez-Garcia 2006 study had a third arm with inhaled
fluticasone 500 µg/day and we combined this data with the 1000
µg/day arm and compared them as a single group with the control
group wherever possible.
The study duration ranged from a short duration of four to six
weeks in the Elborn 1992, Joshi 2004 and Tsang 1998 studies
to six months in the Martinez-Garcia 2006 and Hernando 2012
studies. Two studies were of one year duration (Tsang 2004; Tsang
2005), with visits at four, 12, 24, 36 and 52 weeks.
Outcomes
Lung functions were available as an outcome variable in all stud-
ies except the Tsang 2004 study, which reported only fractional
exhaled nitric oxide (FeNO) levels. Forced expiratory volume in
the first second (FEV1) and forced vital capacity (FVC) (in litres
or % predicted) were available from all studies. Peak expiratory
flow rate (PEFR) was reported in the Elborn 1992, Joshi 2004 and
Tsang 1998 studies, with the Martinez-Garcia 2006 and Tsang
1998 studies giving details about total lung capacity, residual vol-
ume and diffusion capacity. We did not include spirometric pa-
rameters from the Joshi 2004 study in the final analysis since the
’pre-treatment’ values were reported for the whole 20 group to-
gether and these values were not available separately for the two
groups at baseline. We also did not include data from the Tsang
1998 and Tsang 2004 studies in the final analysis, since geometric
mean was used instead of arithmetic mean. We did not include
any of the data from the Elborn 1992 study, since pre-cross-over
data were not available separately.
Clinical parameters of cough,wheeze anddyspnoeaweremeasured
differently in different studies. TheElborn1992 study used a visual
analogue scale (VAS) to quantify these symptoms, the Martinez-
Garcia 2006 study defined significant cough as that persisting for
> 50% of days. Dyspnoea was measured by using the transition
dyspnoea index in theMartinez-Garcia 2006 study.TheHernando
2012 studymeasured cough, sputum production and dyspnoea on
a scale of 0 to 3 and combined these three as a total symptom score.
Clinical parameters of cough, dyspnoea and wheezing, although
reported by the Tsang 2005 study, were not defined properly and
we did not include them in the analysis. Twenty-four-hour sputum
volume was included as an outcome variable in the Elborn 1992,
Martinez-Garcia 2006, Tsang 1998 and Tsang 2005 studies.
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Quality of life was included as an outcome parameter in the
Martinez-Garcia 2006 and Hernando 2012 studies, with both
using the St. George Respiratory Questionnaire to calculate total
scores as well as symptoms, activity and impact score.
The Martinez-Garcia 2006, Tsang 1998 and Tsang 2005 studies
defined exacerbation as persistent (> 24 hours) deterioration in
at least three respiratory symptoms (including cough, dyspnoea,
haemoptysis, increased sputum purulence or volume, and chest
pain), with or without fever, radiographic deterioration, systemic
disturbances, or deterioration in chest signs. The Hernando 2012
study defined exacerbation as worsening of more than 48 hours
duration of at least three of the four symptoms of cough, sputum
production, dyspnoea and fever.
The study characteristics are described in the ’Characteristics of
included studies’ table.
Excluded studies
We excluded five studies from the review. The reason for their
exclusion is discussed in the ’Characteristics of excluded studies’
table. The most common reason for exclusion was the study not
being a RCT (two studies).
Risk of bias in included studies
Risk of bias judgements for included studies are summarised in
Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The generation of randomisation sequence was not reported in six
studies and so we judged risk of bias to be unclear (Elborn 1992;
Joshi 2004; Martinez-Garcia 2006; Tsang 1998; Tsang 2004;
Tsang 2005).Only one study stated how the random sequence was
generated and we judged this to have low risk of bias (Hernando
2012). Allocation concealment was unclear in all seven studies (
Elborn 1992;Hernando 2012; Joshi 2004;Martinez-Garcia 2006;
Tsang 1998; Tsang 2004; Tsang 2005).
Blinding
We judged all studies as low risk as they were double-blind, ex-
cept Martinez-Garcia 2006, which we judged as high risk as they
did not have a placebo arm, and the blinding was done only for
comparing two dosages of ICS.
Incomplete outcome data
Two studies reported the progress of all randomised participants in
each group (Tsang 1998; Tsang 2004), resulting in low risk of bias,
whereas in Joshi 2004, the biaswas unclear as therewas nomention
of withdrawals or dropouts. We judged four studies as high risk
of bias as they did not describe where their dropouts occurred
(Elborn 1992; Hernando 2012; Martinez-Garcia 2006; Tsang
2005). Furthermore, we could not extract pre-cross-over arm data
fromElborn 1992 or include it in any of themeta-analysis. Follow-
up was between 80% to 90% in Tsang 2005 and was unclear in
Joshi 2004. The remaining studies reported outcomes in > 90% of
the participants (Hernando 2012; Martinez-Garcia 2006; Tsang
1998; Tsang 2004).
Selective reporting
We judged six studies to have low risk of bias (Elborn 1992;
Hernando 2012; Joshi 2004; Tsang 1998; Tsang 2004; Tsang
2005), as they reported all data for outcomes. One study did not
report all the outcome data for the 500 µg/day arm (Martinez-
Garcia 2006), therefore we judged it at high risk of bias.
Other potential sources of bias
We judged six studies as potentially having high risk of bias in other
areas (Elborn 1992; Joshi 2004; Martinez-Garcia 2006; Tsang
1998; Tsang 2004; Tsang 2005). The baseline values for lung
functions, sputum amount and sputum inflammatory markers
were significantly different clinically between the arms in three
studies (Tsang 1998; Tsang 2004; Tsang 2005).We judged Elborn
1992 as high risk due to the cross-over design with no washout
period. Joshi 2004 included participants with significant post-
bronchodilator response which indicates ICS would be beneficial.
Martinez-Garcia 2006 did not complete ITT analysis.
Effects of interventions
See: Summary of findings for the main comparison Inhaled
corticosteroids compared to placebo for bronchiectasis (short-term
use of 6 months or less); Summary of findings 2 Inhaled
corticosteroids compared to placebo for bronchiectasis (longer-
term use of > 6 months)
The seven studies involved 380 participants, with 348 completing
the studies (Elborn 1992; Hernando 2012; Joshi 2004; Martinez-
Garcia 2006; Tsang 1998; Tsang 2004; Tsang 2005). The data that
we could include in the meta-analysis were very limited, with just
two studies contributing most data (Hernando 2012; Martinez-
Garcia 2006).
Stable state bronchiectasis: short-term (≤ 6 months)
outcomes
We included data from the Hernando 2012 and Martinez-Garcia
2006 studies in the short-term stable state analysis. See Summary
of findings for the main comparison for the main comparisons.
Primary outcome: lung function
We included date from two studies in this meta-analysis (
Hernando 2012; Martinez-Garcia 2006). We used change from
baseline data to remove bias in differences at baseline. For both
FEV1 and FVC, we combined data of the two steroid dose arms
for theMartinez-Garcia 2006 study into a single intervention arm
when comparing against the no steroid arm. For FEV1, the pooled
data showed no difference between the groups (mean difference
(MD) -0.09, 95% confidence interval (CI) -0.26 to 0.09; partici-
pants = 156; Analysis 1.1). A similar result was seen for FVC (MD
0.01, 95%CI -0.16 to 0.17; participants = 156; Analysis 1.1), with
no significant heterogeneity between studies. The Elborn 1992
study also reported an improvement in the FEV1 in the ICS group
compared to the placebo group (P = 0.03), but not in FVC; as the
values were not reported, we were unable to pool this.
Based on a single study from which we could include data in the
final analysis, ICS showednodifference in the following outcomes:
diffusing capacity of the lungs for carbonmonoxide (DLCO) (MD
2.70, 95% CI -2.49 to 7.89), residual volume (MD 2.00, 95% CI
-9.41 to 13.41) and total lung capacity (MD 3.20, 95% CI -1.99
to 8.39) . We only used the 500 µg twice daily arm, since data
on the lower dose ICS arm were not available (Martinez-Garcia
2006).
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Secondary outcome: clinical severity
We could only display data from a single non-placebo study for
these clinical parameters (Martinez-Garcia 2006). We combined
data from the two ICS dose arms for wheeze and sputum pro-
duction, but not for dyspnoea, since lower dose steroid data were
unavailable. The number of participants with sputum reduction
as well as with improvement in dyspnoea was significantly higher
in the ICS arm compared to the control arm (Analysis 1.3). There
were no differences between groups for the clinical parameters of
cough and wheeze. Although the Martinez-Garcia 2006 study de-
scribed a significant difference between groups for the number of
participants experiencing reduced cough, we found no difference
between groups when we performed ITT analyses. Also, as the
methodology of subjective cough measures was not a validated
method, we did not display this data as a forest plot. Although
we did not include date from the Elborn 1992 study in the final
analysis, the study reported that the ICS group had a significant
improvement in cough (P = 0.02) but not wheeze and dyspnoea.
Again, only the P value was reported. The data from theHernando
2012 study showed no significant improvement in the total symp-
tom score in the group on ICS compared to control (MD -3.22,
95% CI -8.15 to 1.71), but we could not include the data since
the subdivision of the score was not available. None of the other
studies reported these clinical outcomes.
Secondary outcome: exacerbations
Data on average number of exacerbations per participant were
available from two studies (Hernando 2012; Martinez-Garcia
2006). The combined data showed no difference between the two
groups (MD -0.17, 95% CI -0.56 to 0.22; participants = 127;
Analysis 1.4). In the Tsang 1998 study, one participant in the flu-
ticasone group experienced an exacerbation compared with three
participants in the placebo group. In the Hernando 2012 study,
the mean numbers of exacerbations in the ICS group was 0.68
compared to 0.97 in the placebo group, though this was not re-
ported to be statistically significant. In the same study, a much
higher proportion of participants (12%) needed hospital admis-
sion in the placebo group compared to the ICS group (2.7%), but
this was not statistically significant. We only used the 500 µg twice
daily arm for the Martinez-Garcia 2006 study, since data on the
lower dose ICS arm were not available for this parameter.
Secondary outcome: sputum and biomarker characteristics
The Martinez-Garcia 2006 study was the only study included
in this analysis which showed a trend towards reduction in the
sputum volume (MD -8.30, 95% CI -16.55 to -0.05; participants
= 57; Analysis 1.5). We only used the 500 µg twice daily arm
for the Martinez-Garcia 2006 study, since data on the low dose
ICS arm were not available. We did not include data on sputum
volume and sputum inflammatory markers from the Tsang 1998
study in the final analysis due to clinically significant differences in
the baseline value between the two groups. The Elborn 1992 study
also described a significant improvement in the 24-hour sputum
volume in the ICS group (P = 0.003), but neither the size of the
effect nor the CI was provided. The other studies did not include
this as an outcome variable.
Secondary outcome: fractional exhaled nitric oxide (FeNO)
TheTsang 2004 study showedno change in the FeNObetween the
two groups at 24 weeks. Since the data were skewed and geometric
means were reported, we did not include this data in the analysis.
The proportion of eosinophils as a percentage of total cells were
significantly less in the sputum at the end of ICS therapy com-
pared to the end of placebo therapy in the Hernando 2012 study,
although all other inflammatory sputum markers, including IL-8,
did not show any significant difference.
Secondary outcome: Pseudomonas colonisation
Data on proportion of participants colonised with P aerugi-
nosa at the end of treatment were available from two studies
(Hernando 2012;Martinez-Garcia 2006), with pooled data show-
ing no increased risk of P aeruginosa colonisation with ICS ther-
apy. We used combined data for the two steroid dose arms for the
Martinez-Garcia 2006 study for this parameter.We included extra
data provided by the Hernando 2012 study in this analysis.
The Tsang 1998 study explained that the density of P aeruginosa
in the sputum was similar between groups at the end of treatment
(median density of 1.0 x 10E7 cfu/mL (inter-quartile range (IQR)
0.33 to 5.15) in the ICS group and 1.4 x 10E7 cfu/mL (IQR 0.7
to 4.67) in the placebo group.
However, the density of total bacteria and commensal bacteria
in sputum increased after four weeks of therapy with ICS when
compared to baseline (median baseline value was 2.6 x 10E7 cfu/
mL (IQR 0.94 to 5.28) andmedian post-treatment value was 11.6
x 10E7 cfu/mL (IQR 0.34 to 33.8) whilst the corresponding value
in the placebo group was lower post-treatment (median baseline
value was 2.6 x 10E7 cfu/mL (IQR 0.34 to 4.3) and median post-
treatment value was 1.3 x 10E7 cfu/mL (IQR 0.55 to 2.75). The
post-treatment between-group comparisons P value did not reach
statistical significance (P = 0.06) (Tsang 1998).
Secondary outcome: quality of life
Data were available from two studies (Hernando 2012; Martinez-
Garcia 2006).When data of the two ICS dose armswere combined
in the Martinez-Garcia 2006 study, and clinical improvement in
health-related quality of life (HRQoL) analysed as a dichotomous
variable, significantly more people in the ICS group experienced
a clinically important improvement in their HRQoL score com-
pared to the no treatment group (Analysis 1.3.4). The Hernando
2012 study reported worsening in total quality of life score in
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both the ICS and placebo group when compared to baseline, but
the between-group difference was not statistically significant (MD
-3.22, 95% CI -8.15 to 1.71; participants = 70; Analysis 1.7).
Whenwe pooled the data from the two included studies, there was
a statistically significant improvement in activity score but not for
total scores or symptom score (Analysis 1.7). Only 500 µg twice
daily ICS data were available for these parameters. Impact score
data were only available from the Hernando 2012 study.
Secondary outcome: adverse events
Only one study reported adverse events (Martinez-Garcia 2006),
and it was more frequent in the treatment group receiving 1000
µg versus 500 µg (19 participants versus 7, P = 0.04). The most
common side effects were dry mouth, local irritation and transient
dysphonia.
Stable state bronchiectasis: long-term (> 6 months)
outcomes
We included data from the Tsang 2004 study and Tsang 2005
study in the long-term stable state analysis, although the Tsang
2004 study had only FeNO as the outcome variable. See Summary
of findings 2 for the main comparisons.
Primary outcome: lung function
For FEV1 % predicted (end study minus baseline values), data
from the single study, Tsang 2005, showed no difference between
the two groups (MD 0.30, 95% CI -17.43 to 18.03; participants
= 86; Analysis 2.1).
For FVC%predicted (end studyminus baseline values), data from
the single study, Tsang 2005, showed no difference between the
two groups (MD -0.90, 95% CI -14.59 to 12.79; participants =
86; Analysis 2.1).
Secondary outcome: clinical severity
We did not include any data for the clinical parameters from the
two studies of more than six months duration (Tsang 2004; Tsang
2005).
Secondary outcome: exacerbations
The Tsang 2005 study showed a non-significant improvement in
exacerbation frequency in the ICS group compared to the control
group (odds ratio (OR) 0.57, 95% CI 0.24 to 1.34; participants
= 86; Analysis 2.2).
Secondary outcome: sputum and biomarker characteristics
As an overall effect, ICS had no effect on the 24-hour sputum
volume when given for a period of 52 weeks, although we did
not include the data for this outcome in the analysis because only
median and interquartile ranges were available and the data were
very skewed. As a subgroup analysis, theTsang 2005 study reported
a significant improvement in the amount of sputum volume/day
in the subgroup of participants with sputum volume < 30 mL/
day, exacerbation frequency ≤ two/year, and sputum purulence
score > 5 (data not available).
Sputum purulence was scored as 0, 1, 2, 3, 4, 5, 6, 7 or 8 (absence
of, completely transparent, almost transparent, translucent but
colourless, opaque,milkywhite grey, pale green,moderately green,
and dark green sputum, respectively) in the Tsang 2005 study.
After 52weeks, there was no significant difference in the purulence
scores between the ICS and placebo groups (MD 0.2, 95% CI -
0.94 to 1.34; participants = 86; Analysis 2.3).
Secondary outcome: FeNO
The Tsang 2004 study showed no change in the FeNO between
the two groups at 52 weeks, although we did not include the data
due to its skewed nature.
Secondary outcome: adverse events
None of the studies reported adverse events.
Sensitivity analysis
Removing the study with a poor quality score (no placebo) made
no difference to the results for FEV1 and FVC. The activity sub-
score of the St. George Respiratory Questionnaire (a measure
of HRQoL) became non-significant when we removed the non-
placebo controlled study (Martinez-Garcia 2006).
For the clinical data, whenwe analysed separately the data from the
fluticasone 1000 µg arm of the Martinez-Garcia 2006 study and
the 500 µg arm, in both arms in the meta-analysis, those on ICS
still had a higher proportion of participants with sputum volume
reduction of > 50%. For the outcomes of wheeze and cough there
was still no difference between the groups. For the outcome of
dyspnoea, actual data were not provided for the 500 µg arm but
the study authors mentioned that there was no difference between
groups. Hence it is assumed that the significant effect present for
the 1000 µg/day group (outcome 1.3.3) was no longer present for
the 500 µg/day group.
Analysis using random-effects did not alter the significance of any
of the outcomes. None of the other planned sensitivity analysis
were relevant.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Inhaled corticosteroids compared to placebo for bronchiectasis (medium- to long- term outcomes)
Patient or population: people with bronchiectasis
Setting: university hospital
Intervention: inhaled cort icosteroids
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with Inhaled corti-
costeroids
Lung funct ion indices -
FEV1% predicted (end
study minus baseline
values)
Mean change f rom
baseline 0
MD 0.30 higher
(17.43 lower to 18.03
higher)
- 86
(1 study)
⊕⊕©©
Low1,2
Lung funct ion indices -
FVC % predicted (end
study minus baseline
values)
Mean change f rom
baseline 0.9
MD 0.90 lower
(14.59 lower to 12.79
higher)
- 86
(1 study)
⊕⊕©©
Low1,2
Number of part icipants
improved
628 per 1000 490 per 1000
(288 to 693)
OR 0.57
(0.24 to 1.34)
86
(1 study)
⊕⊕©©
Low1,2
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; FEV1: f orced expiratory volume in 1 second; FVC: f orced vital capacity; MD: mean dif ference; OR: odds rat io
GRADE Working Group grades of evidence
High-certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate-certainty: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low-certainty: our conf idence in the ef fect est imate is lim ited; the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low-certainty: we have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect18
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D I S C U S S I O N
Summary of main results
We did not identify any studies involving children in our searches.
Seven studies involving adult participants fulfilled the inclusion
criteria. Of the 380 randomised, 348 participants completed the
trials. In the short-term group ( inhaled corticosteroids (ICS) for
≤ 6 months), use of high dose ICS in adults with bronchiectasis
did not lead to any statistical or clinically significant change in the
lung function indices of forced expiratory volume in the first sec-
ond (FEV1) and forced vital capacity (FVC). Further, there was no
statistically significant improvement in the overall health-related
quality of life (HRQoL) indices except in the activity score. There
was improvement in sputum production and dyspnoea scores in
the ICS group from the single study with available data for this
outcome (Martinez-Garcia 2006), but the result should be in-
terpreted with caution as the study was not placebo controlled.
When we only included placebo controlled studies, there were no
significant differences between groups in all outcomes examined
(spirometry, clinical outcomes of exacerbation or sputum volume,
etc.). The single study on long-term outcomes showed no signifi-
cant benefit of ICS in any of the outcomes.
Overall completeness and applicability of
evidence
This Cochrane review is limited to seven studies involving adult
participants with variable designs, variable doses and length of
study. Also, data that could be combined for the meta-analyses
were limited to only two studies for the various outcomes exam-
ined. As there were no paediatric studies, data from this review
cannot be extrapolated to children. Further, in children, the ad-
verse effect of high dose, or long-term ICS, or both, is likely to be
more serious than in adults, in particular to the detrimental effect
on linear growth (Philip 2014).
The meta-analyses derived from two studies of the short-term
effect of ICS in bronchiectasis showed no benefit of ICS on lung
function parameters of FEV1 and FVC (compared to controls),
though the data includedwere limited (Hernando2012;Martinez-
Garcia 2006). There was improvement in clinical parameters of
dyspnoea and sputum production in the ICS group, based on data
from the single study which was not placebo controlled. Similar
improvement was also seen in the activity score of HRQoL in
the ICS group, though the effect was marginal. We could not
include data from Joshi 2004 and Tsang 1998 in the final analysis,
but both studies had not reported any improvement in the lung
function parameters between the steroid and placebo groups. On
the contrary, data from the Elborn1992 study (whichwe could not
include in themeta-analysis) showed a significant improvement in
the FEV1 in the ICS group compared to the placebo group. Thus,
it remains uncertain whether ICS confers any benefit in people
with bronchiectasis.
Data on the short-term effect of ICS on clinical parameters
of cough, wheeze, dyspnoea and sputum volume were available
from two studies (Hernando 2012; Martinez-Garcia 2006). The
Martinez-Garcia 2006 study showed a significant improvement
in dyspnoea in the 1000 µg/day fluticasone group and sputum
volume for the combined 500 µg/day and 1000 µg/day group
compared to the control group, although no such effect was seen
in the total symptom score from the Hernando 2012 study. We
did not include data on sputum volume from the Tsang 1998
study in the analysis in view of the clinically significant difference
in the baseline values. The Martinez-Garcia 2006 study showed
a significant improvement in the quality of life score in the ICS
group using the St. George Respiratory Questionnaire, though no
such improvement was reported in the Hernando 2012 study. On
pooling these data, the effect favoured ICS use largely due to the
large effect of the non-placebo controlled study (Martinez-Garcia
2006).
Recurrent acute pulmonary exacerbations form part of the disease
progression in patients with bronchiectasis andmany of these exac-
erbations require hospital admission. Recurrent exacerbations are
associated with progressive deterioration of lung functions (Kapur
2010), and are also one of the strong predictors of poor quality
of life in bronchiectasis (Wilson 1997). In this review, based on
limited data, short-term use of ICS did not influence frequency
of exacerbations. Prolonged ICS administration also did not in-
fluence exacerbation frequency (Tsang 2005). This becomes more
relevant with the fact that ICS actually increased the bacterial den-
sity in the airways and most exacerbations in bronchiectasis are
likely to be infective in origin (Tsang 1998).
Administration of ICS for a longer duration significantly increased
the number of participants who had a more than 20% reduction
in the 24-hour sputum volume, but did not have any beneficial
effect in the other clinical or spirometric parameters (Tsang 2004;
Tsang 2005). This lack of effect again suggests that infection and
not pure inflammation, is probably the more relevant underlying
pathogenic mechanism of disease progression in bronchiectasis.
The ICS doses used in several studies were very high (up to 2000
µg/day budesonide equivalent). This limits applicability of the
data to most patients in our current era where ICS doses used
are generally lower, in light of the increased appreciation of ad-
verse events related to prolonged use of high ICS doses, such as
the effect on linear growth (Philip 2014). High dose ICS use is
also associated with adverse events in children and adults that
range from mild events (candidiasis) to serious events (pneumo-
nia, adrenal insufficiency, osteoporosis, cataracts) (Sobieraj 2008).
TheMartinez-Garcia 2006 study reported dry mouth, local irrita-
tion and transient dysphonia as the most common adverse effects.
None of the other studies reported any adverse effects.While there
was no significant difference in adverse events between groups,
the total sample size was small, rendering a likely type-1 error.
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The potential harm associated with prolonged ICS use, or high
ICS doses, or both, need to be considered along with its potential
benefit.
Bronchiectasis is a heterogenous condition, with a substantial
overlap in people with chronic obstructive pulmonary disease
(COPD). Not all the studies in this review excluded smokers and
thus, whether data in our review can be universally applied is un-
known. Nearly 50% of adults with COPD have bronchiectasis
(Chang 2008). A Cochrane Review concluded that ICS admin-
istration reduces the rate of exacerbations as well as the rate of
decline in quality of life in patients with stable state COPD (Yang
2012). As the Martinez-Garcia 2006 study included participants
who were smokers, there is a possibility that some of these par-
ticipants had COPD and this may influence the positive findings
in that study. It is possible that COPD-associated bronchiectasis
may respond differently to treatment modalities when compared
to bronchiectasis associated with other causes.
Persistent inflammation plays a role in deterioration of lung func-
tion in bronchiectasis (Ip 1993). Studies in adults with cystic fibro-
sis suggest that ICS treatment improves bronchial hyper-respon-
siveness and spirometric parameters (Van Haren 1995). Thus, it
is theoretically possible that ICS may improve lung function, and
with it clinical parameters in non-cystic fibrosis bronchiectasis as
well, although this review has shown that any benefit from ICS is
inconsistent. However, given the increased presence of airway hy-
per-responsiveness in patients with non-cystic fibrosis bronchiec-
tasis (Ip 1991), it is possible that ICS may have a role in this sub-
group.
The bacteriology of sputum influences future morbidity and mor-
tality; specifically, people with Pseudomonas aeruginosa (P aerugi-
nosa) have more rapid lung function decline (Finch 2015). As the
bacteriology in all the included studies were unclear, the applica-
bility of this review in the different subsets of people with various
bacteriology such as mycobacteria and P aeruginosa is also uncer-
tain.
In the consideration of using ICS, especially long-term ICS (> 6
months) in patients, clinicians should be cognisant of the possible
effect of corticosteroids on cell immunity dysregulation (Sabroe
2013). Biologically, this effect could lead to an increase in infec-
tions that could worsen clinical outcomes, such as lung function
and exacerbations (Sabroe 2013). Indeed, adults with COPD on
ICShave an increased unadjusted risk of having pneumonia (Festic
2016). Although this adverse event is a clinically important issue
in people with bronchiectasis, only one study specifically reported
on adverse events and thus we could not assess this in this review.
However, in the ICS group of shorter duration (6 months or less),
two studies found no increased risk of P aeruginosa in the ICS
arm compared to placebo (Analysis 1.6). One study found a non-
significant increase in sputum bacterial density in the ICS group
(Tsang 1998), whilst there was a non-decrease in the placebo group
(between-groups post-treatment P = 0.06).
Quality of the evidence
The overall quality of evidence was low (Summary of findings for
the main comparison; Summary of findings 2). The sample size
and number of studies were small. The major contributor to the
benefit of ICS found in the meta-analyses was from a non-placebo
controlled study. The studies also did not exclude participants
with airway hyper-responsiveness or coexistent COPD, hence the
potential of skewing the results in favour of ICS.
Potential biases in the review process
We conducted this review in accordance with a prespecified proto-
col.We have outlined changes from the protocol in theDifferences
between protocol and review section and we did not identify any
major sources of bias in the review process.
Agreements and disagreements with other
studies or reviews
Our findings are similar to that outlined in bronchiectasis guide-
lines of the British Thoracic Society (Pasteur 2010), and the Tho-
racic Society of Australia and New Zealand (Chang 2015). We
found no other published systematic reviews on the use of ICS for
people with bronchiectasis.
Whilst a separate disease, cystic fibrosis lung disease manifests with
bronchiectasis. Studies in cystic fibrosis have also shown no ben-
efits with ICS. A Cochrane Review of ICS in cystic fibrosis con-
cluded that there is insufficient evidence to determine if they are
beneficial or harmful (Balfour-Lynn 2014). In a large prospective,
multicentre study, withdrawal of ICS for six months was not as-
sociated with significant worsening of cystic fibrosis lung disease
(Balfour-Lynn 2006). Participants in whom ICS were discontin-
ued did not have a change in lung function over time, an increased
need for oral or intravenous antibiotics, or a shorter time to pul-
monary exacerbation (Balfour-Lynn 2006).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In this reviewupdate, we identified one new study, adding a further
77 participants; however, these additional results did not change
the original conclusions. The present review continues to indicate
that there is insufficient evidence to suggest the routine use of in-
haled corticosteroids (ICS) in adults with stable state bronchiecta-
sis. The only study that showed a benefit was a non-placebo con-
trolled trial (Martinez-Garcia 2006). Insufficient data precludes
any definite conclusion on the use of ICS in adults during an acute
exacerbation, or in children (for any state) as there were no studies.
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Implications for research
Further studies are required to examine the effect of ICS on short-
and long-term outcomes for children and adults with non-cys-
tic fibrosis bronchiectasis. Outcomes should include exacerbations
(rate and hospital admission), symptoms, quality of life, lung func-
tion indices and inflammatory parameters and bacteriology. Stud-
ies are required in both stable state and during an acute exacerba-
tion state. Studies involving adults should clearly differentiate co-
existent COPD, as the presence of this may influence effectiveness
of ICS. A priori analysis for those with bronchial hyper-respon-
siveness should also be defined, since its presence may influence
ICS response.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Elborn 1992
Methods Aprospective, double-blind, placebo controlled, randomised cross-over designwith study
duration of 6 weeks
There were five participants who dropped out; we are unsure when these occurred. Two
participants declined to take part in second limb of study
No washout period mentioned.
Participants Twenty participants (12 females, mean age 50 years, range 30 to 65) were studied with
bronchiectasis diagnosed by bronchogram in 18 and computed tomography scan in two.
No participant received a course of antibiotics for at least 8 weeks prior to the study
Exclusion: participants with hypogammaglobulinaemia, cystic fibrosis, ABPA or primary
ciliary dyskinesia, as well as those taking OCS or ICS
Interventions Inhaled beclomethasone dipropionate 750 µg twice daily byMDI or placebo for 6 weeks
Outcomes • FEV1
• FVC
• PEFR (morning and evening)
• 24-hour sputum amount collected weekly from patients
• visual analogue scale for cough, wheeze and dyspnoea recorded on a diary card
and on a 75 mm line (higher value better)
Notes Cross-over design with no washout period. Separate results of first arm not available.
Data not included in analysis. No funding source mentioned, though acknowledgement
for ICS was given to Allen and Hanburys
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information was provided within the
published article about generation of ran-
domisation
Allocation concealment (selection bias) Unclear risk No information about concealment was re-
ported in the article
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “double-blinded” and “matched
placebo”.
Incomplete outcome data (attrition bias)
All outcomes
High risk There were 5 patients who dropped out;
we are unsure when these occurred. Two
patients declined to take part in second arm
of study
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Elborn 1992 (Continued)
Selective reporting (reporting bias) Low risk No suggestion that selective reporting may
have been done.
Other bias High risk Cross-over design with no washout period.
Separate results of first arm not available
Hernando 2012
Methods A prospective, double-blind, parallel group placebo controlled trial
Participants 77 participants included over a 3-year period. Age range 40 to 85 years, mean age 68.
06 years. Seven did not complete the study: three died from respiratory failure and four
pulled out voluntarily. 37 analysed in the budesonide group and 33 in the placebo group.
Mean age of the budesonide group was 68 years and that of the placebo group was 66
years. 19 (27.1%) participants in the budesonide group and 18 (25.7%) in the placebo
group had Pseudomonas aeruginosa (P aeruginosa) cultured from their sputum. The mean
(SD) baseline FEV1% predicted in the budesonide and the placebo group was 64.6%
(25.1) and 64.7% (27), respectively
Interventions 400 µg inhaled budesonide twice a day versus placebo for 6 months
Outcomes Total symptom score which included I) cough and sputum production; and ii) dyspnoea
• Proportion with exacerbations
• Hospital admission
• FEV1 difference
• FVC difference
• SGRQ
• Sputum IL-8 & cellularity
• Microbiological changes including percentage P aeruginosa positive at the end of 6
months
Notes Additional information provided by the authors. The studywas supported by theCatalan
Foundation of Pneumology grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Hospital pharmacy (third party) performed
randomisation and dispensed inhalers
Allocation concealment (selection bias) Unclear risk No mention how allocation was done.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote “parallel, placebo-masked clinical
trial”. Probably done
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Hernando 2012 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 7 dropouts, 6 of whom were from the
placebo group. Data of dropouts not in-
cluded. Since 3 of these died of respiratory
failure, all belonging to the placebo group,
potential for bias on outcome if data not
included
Selective reporting (reporting bias) Low risk No suggestion that selective reporting may
have been done.
Other bias Low risk No other risk of bias identified
Joshi 2004
Methods Randomised double-blind, placebo controlled, cross-over study with study duration of
4 weeks
Two-week washout period between cross-over.
Details of dropouts not clear.
Participants 20 participants (9 females) age range 15 to 60 years were prospectively enrolled. All
participants treated with oral salbutamol 2 mg four times daily and oral theophylline
200 mg four times daily throughout the trial period
14 participants had unilateral disease and six had bilateral disease
Inclusion: bronchiectasis confirmed by HRCT, chest in stable state (no exacerbation
in previous 1 month) demonstrating significant post-bronchodilator response (> 12%
change) on spirometry
Exclusion: atopy, bronchial asthma or smoking
Interventions Inhaled beclomethasone 800 µg/day in two divided doses byMDI or placebo for 4 weeks
Outcomes • FVC at 4 weeks and 10 weeks
• FEV1 at 4 weeks and 10 weeks
• PEFR at 4 weeks and 10 weeks
Notes SD calculated from P value. Only first arm of the study before cross-over used in analysis.
Additional information provided by the authors. Spirometeric data not included in the
analysis since baseline values not reported separately for the two groups and a common
mean given for the group of 20. No mention of funding source
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information was provided within the
published article about generation of ran-
domisation
Allocation concealment (selection bias) Unclear risk No mention how allocation was done.
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Joshi 2004 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “patientswere randomised in a dou-
ble blind manner”. Comment: Probably
done
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No mention of dropouts.
Selective reporting (reporting bias) Low risk No suggestion that selective reporting may
have been done.
Other bias High risk Inclusion of participants who had a sig-
nificant post-bronchodilator response bi-
ased the study in favour of response to ICS
since those with positive bronchodilator re-
sponse are more likely to improve with ICS
due to the asthma-like reversibility in their
airway
Martinez-Garcia 2006
Methods Randomised (stratified for prior smoking habit in pack year), double-blind (only for
dose of steroid), non-placebo controlled prospective trial with study duration 6 months
Participants Of the 132 participants initially included in the study, 39 were excluded prior to ran-
domisation (23 had high probability of asthma, 4 did not give consent, 1 had Down’s
syndrome and 3 each had psychiatric disorder, systemic ICS and had disease of significant
severity). 93 patients enrolled in the study
Seven dropouts during the study, three from the no steroid group and two each from
the 500 µg and 1000 µg group. Study completed in 86 participants
• No steroid group n = 28: mean age 70.9 (SD 6.1), 17 males
• 500 µg/day fluticasone group n = 29: mean age 66.4 (SD 12.6), 18 males
• 1000 µg/day group n = 29: mean age 70.9 (SD 6), 21 males
Inclusion: all participants withHRCTdiagnosed bronchiectasis diagnosed between 1993
and June 2003 in Requena General Hospital. The participants were required to be free
from acute exacerbation for at least 4 weeks
Exclusion: participants with asthma, cystic fibrosis and on whom ICS could not be
stopped
Interventions Inhaled fluticasone 500 µg twice daily by MDI versus 250 µg fluticasone twice daily
versus no treatment for 6 months
Outcomes Baseline data collection started 6months prior to randomisation. During this period data
prospectively collected on number of acute exacerbations, antibiotic use and hospital
admissions
• FEV1, FVC, TLC, RV and diffusion capacity measured a few days prior to
randomisation.
During randomisation visit, information collected on dyspnoea score, daily sputum
production (average of sputum produced over three days); cough and need for short-
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Martinez-Garcia 2006 (Continued)
acting bronchodilator in the 1-month prior to randomisation, and HRQoL using the
validated Spanish version of the SGRQ
After randomisation, TLC, RV and diffusion capacity analysed again after 6 months.
HRQoL assessment at 3 and 6 months and all other tests at 1, 3 and 6 months
> 4-point change in SGRQ considered significant. > 1-point change is dyspnoea score
considered significant
Notes Wherever available, data on the 250 µg twice daily group was combined with 500 µg
twice daily group for comparisonwith no steroid group. Additional information provided
by the authors. Study was supported by Grant Red Respira
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information was provided within the
published article about generation of ran-
domisation
Allocation concealment (selection bias) Unclear risk No mention of how allocation was done.
Blinding (performance bias and detection
bias)
All outcomes
High risk Quote: “The study was conducted on a
double blind basis regarding the effective
inhalatory steroid dose administered (500
vs. 1000 µg/day), but not as relates to the
administration or not of steroid treatment
(i.e. 0 vs. 500 or 1000 µg/day).”
Comment: No blinding for the two groups
assessed by us (0 versus 1000 µg/day)
Incomplete outcome data (attrition bias)
All outcomes
High risk The patient characteristics and outcome
data of those excluded or dropped out not
described and not compared with those in-
cluded for analysis
Selective reporting (reporting bias) High risk Information onTLC, RV andDLCOgath-
ered but not reported. Some outcomes that
were reported in the 1000 µg group were
not reported in the 500 µg group (such as
sputum volume, TLC, RV and cough and
wheeze clinical variables)
Other bias High risk Intention-to-treat analysis not done.Of the
39 participants excluded before randomi-
sation, no details available for the reason
for exclusion for 2 participants
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Tsang 1998
Methods Randomised double-blind, placebo controlled prospective trial with study duration of 4
weeks
There were no dropouts.
Participants 24 participants (mean age 51 years, 12 females) with HRCT proven bronchiectasis
Fluticasone group: n = 12, 6 females, age: mean 43 (SD 11). Placebo group: n = 12, 8
females, age: mean 56.8 (SD 11)
Inclusion: daily sputum > 10 mL, absence of asthma or other unstable systemic disease;
and “steady state” bronchiectasis (< 10% alteration of 24-hour sputum volume, FEV1
and FVC).
Exclusion: unreliable clinic attendance, known adverse reaction to fluticasone, regular
use of ICS and asthma
Interventions Inhaled fluticasone 500 µg twice daily by accuhaler or placebo for 4 weeks
Outcomes • FEV1
• FVC
• TLC
• RV
• Diffusion capacity
• PEFR
• 24-hour sputum volume (mean of 3 days)
Sputum leukocyte density, bacterial densities and concentrations of interleukin (IL)1B,
IL 8, TNF alpha and leukotriene B4 were all measured at the time of randomisation and
at 4 weeks
Notes Geometric mean was used instead of arithmetic mean. Hence, none of the lung function
data were included in the final analysis. No mention of funding source
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information was provided within the
published article about generation of ran-
domisation
Allocation concealment (selection bias) Unclear risk No mention of how allocation was done.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “performed a double blind, placebo
controlled study”. Comment: Probably
done
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no dropouts.
Selective reporting (reporting bias) Low risk No suggestion that selective reporting may
have been done.
31Inhaled corticosteroids for bronchiectasis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tsang 1998 (Continued)
Other bias High risk The baseline values for lung functions, spu-
tum amount and sputum inflammatory
markers were significantly different, thus
were subject to bias
Tsang 2004
Methods Randomised double-blind, prospective placebo controlled trial with study duration of
52 weeks
There were no dropouts.
Participants 60 participants (mean age 56.4 years, 38 females) with HRCT proven bronchiectasis
Fluticasone group: n = 30, age: mean 56.1 (SD 14). Placebo group: n = 30, age: mean
56.7 (SD 11.3)
16 were P aeruginosa colonised and 44 were not.
Inclusion: absence of asthma or other unstable systemic disease; and “steady state”
bronchiectasis (< 20% alteration of 24-hour sputum volume, FEV1 and FVC) and ab-
sence of deterioration in respiratory symptoms at baseline visit
Exclusion: unreliable clinic attendance, knownadverse reaction to fluticasone and asthma
Interventions Inhaled fluticasone 500 µg twice daily by accuhaler or placebo for 52 weeks
Outcomes The participants were followed up at -2, -1, 0, 4, 12, 24, 36, 48 and 52 weeks after
commencement of therapy for measurement of FeNO
Notes Data not included in the final analysis since medians and inter-quartile range reported
in this study. The study was supported by a CRCG Grant of the University of Hong
Kong. The Accuhalers were donated by GlaxoWellcome, China
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information was provided within the
published article about generation of ran-
domisation
Allocation concealment (selection bias) Unclear risk No mention on allocation concealment.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “performed a double blind, placebo
controlled study”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no dropouts.
Selective reporting (reporting bias) Low risk No suggestion that selective reporting may
have been done.
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Tsang 2004 (Continued)
Other bias High risk Baseline value of the 2 groups were signifi-
cantly different.
Tsang 2005
Methods Randomised double-blind, prospective placebo controlled trial with study duration of
52 weeks
5 dropouts in the placebo arm (1 at 4 weeks, 3 at 24 weeks and 1 at 52 weeks) and 8
dropouts in the fluticasone arm (2 at 4 weeks and 1 each at 6, 22, 32, 36, 50 and 52
weeks)
Participants 89 patients recruited. Three participants withdrew. 86 participants (57 females, mean
age 58.5 years) with HRCT proven bronchiectasis randomised between fluticasone and
placebo
Fluticasone group: n = 43, 23 females, age: mean 57.7 (SD 14.4). Placebo group: n =
43, 34 females, age: mean 59.2 (SD 14.2)
23 were P aeruginosa colonised.
Inclusion: absence of asthma or other unstable systemic disease; and “steady state”
bronchiectasis (< 20% alteration of 24-hour sputum volume, FEV1 and FVC) and ab-
sence of deterioration in respiratory symptoms at baseline visit
Exclusion: unreliable clinic attendance, known adverse reaction to fluticasone or
quinolones and regular usage of ICS
Interventions Inhaled fluticasone 500 µg twice daily by accuhaler device or matched placebo for 52
weeks
Outcomes The participants were followed up at -2, -1, 0, 4, 12, 24, 36, 48 and 52 weeks after
commencement of therapy
Primary outcomes
• 24-hour sputum volume (mean of 3 days) and cumulative exacerbation frequency
Secondary outcomes
• Sputum purulence score
• FEV1%
• FVC %
Improvement or deterioration was defined as > 20% change from baseline
Notes SD calculated from P value for sputum volume and exacerbation frequency and from
confidence interval for the rest. The study was partially funded by GlaxoWelcome (Hong
Kong)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomisation (block of 4)”, how-
ever, no information about who generated
the randomisation codes
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Tsang 2005 (Continued)
Allocation concealment (selection bias) Unclear risk No information about concealment was re-
ported in the published article
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “double blind, placebo controlled
study”.
Incomplete outcome data (attrition bias)
All outcomes
High risk Data of dropouts not compared to those
included in analysis.
Selective reporting (reporting bias) Low risk No suggestion that selective reporting may
have been done.
Other bias High risk Significant differences at the baseline on
clinical features of “cough” and “dyspnoea”
between the two groups to allow for post-
treatment comparison
ABPA: allergic bronchopulmonary aspergillosis
DLCO: diffusing capacity of the lungs for carbon monoxide
FeNO: fractional exhaled nitric oxide
FEV1: forced expiratory volume (in 1 second)
FVC: forced vital capacity
HRCT: high resolution computed tomography
HRQoL: health-related quality of life
ICS: inhaled corticosteroids
MDI: metered dose inhaler
OCS: oral corticosteroids
PEFR: peak expiratory flow rate
RV: residual volume
SD: standard deviation
SGRQ: St George’s Respiratory Questionnaire
TLC: total lung capacity
TNF: tumour necrosis factor
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ghosh 2002 Study compared effects of inhaled budesonide with inhaled ipratropium and not placebo
Guran 2008 Not a RCT, withdrawal study with before-and-after outcomes
Martinez-Garcia 2012 Study compared budesonide with budesonide-formoterol combination and not a placebo
34Inhaled corticosteroids for bronchiectasis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Monton 1999 Study included patients with pneumonia and not bronchiectasis. Used systemic steroids, not inhaled
ONeil 2004 Study not a RCT. Studies subjective benefits of inhaler therapy including both ICS and bronchodilators
ICS: inhaled corticosteroids
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Stable state bronchiectasis (6 months or less)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Lung function (spirometry
indices)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 FEV1 (in L, end study
minus baseline values)
2 156 Mean Difference (IV, Fixed, 95% CI) -0.09 [-0.26, 0.09]
1.2 FVC (in L, end study
minus baseline values)
2 156 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.16, 0.17]
2 Lung function (other indices) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Diffusion capacity %
predicted (end of study)
1 57 Mean Difference (IV, Fixed, 95% CI) 2.70 [-2.49, 7.89]
2.2 RV % predicted (end of
study values)
1 57 Mean Difference (IV, Fixed, 95% CI) 2.0 [-9.41, 13.41]
2.3 TLC % predicted (end of
study values)
1 57 Mean Difference (IV, Fixed, 95% CI) 3.20 [-1.99, 8.39]
3 Clinical severity indices 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Number of participants
with regular wheeze
(combined)
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Number of participants
without sputum reduction of >
50% (combined)
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Number of participants
with no improvement in
dyspnoea score > 1 (min
important difference) (1000F)
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 Number of participants
with no clinically significant
improvement in HRQoL
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Exacerbations 2 127 Mean Difference (IV, Fixed, 95% CI) -0.17 [-0.56, 0.22]
4.1 Average number of
exacerbations per participant
2 127 Mean Difference (IV, Fixed, 95% CI) -0.17 [-0.56, 0.22]
5 Sputum and biomarkers
characteristics
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Sputum volume or weight
(per day)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Pseudomonas aeruginosa
colonisation
2 156 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.45, 1.96]
7 St George HRQoL (end of study
minus baseline)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 Total score 2 127 Mean Difference (IV, Fixed, 95% CI) -3.54 [-8.00, 0.92]
7.2 Symptom score 2 127 Mean Difference (IV, Fixed, 95% CI) -4.75 [-10.42, 0.92]
7.3 Activity score 2 127 Mean Difference (IV, Fixed, 95% CI) -6.21 [-12.40, -0.01]
7.4 Impact score 1 70 Mean Difference (IV, Fixed, 95% CI) -3.63 [-9.35, 2.09]
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Comparison 2. Stable state (> 6 months)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Lung function indices 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 FEV1% predicted (end
study minus baseline values)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 FVC % predicted (end
study minus baseline values)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Exacerbations 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Number of participants
improved
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Sputum and biomarker
characteristics
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Sputum purulence score 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Stable state bronchiectasis (6 months or less), Outcome 1 Lung function
(spirometry indices).
Review: Inhaled corticosteroids for bronchiectasis
Comparison: 1 Stable state bronchiectasis (6 months or less)
Outcome: 1 Lung function (spirometry indices)
Study or subgroup
Inhaled
Corticos-
teroids Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 FEV1 (in L, end study minus baseline values)
Hernando 2012 37 0.646 (0.46) 33 0.81 (0.515) 58.7 % -0.16 [ -0.39, 0.07 ]
Martinez-Garcia 2006 58 -0.023 (0.6848) 28 -0.04 (0.5662) 41.3 % 0.02 [ -0.26, 0.29 ]
Subtotal (95% CI) 95 61 100.0 % -0.09 [ -0.26, 0.09 ]
Heterogeneity: Chi2 = 0.91, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
2 FVC (in L, end study minus baseline values)
Hernando 2012 37 0.0174 (0.387) 33 0.02 (0.375) 82.9 % 0.00 [ -0.18, 0.17 ]
Martinez-Garcia 2006 58 -0.007 (0.6795) 28 -0.06 (0.95) 17.1 % 0.06 [ -0.34, 0.45 ]
Subtotal (95% CI) 95 61 100.0 % 0.01 [ -0.16, 0.17 ]
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
-1 -0.5 0 0.5 1
Favours placebo Favours ICS
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Analysis 1.2. Comparison 1 Stable state bronchiectasis (6 months or less), Outcome 2 Lung function (other
indices).
Review: Inhaled corticosteroids for bronchiectasis
Comparison: 1 Stable state bronchiectasis (6 months or less)
Outcome: 2 Lung function (other indices)
Study or subgroup Favours ICS Favours placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Diffusion capacity % predicted (end of study)
Martinez-Garcia 2006 29 86.9 (10) 28 84.2 (10) 100.0 % 2.70 [ -2.49, 7.89 ]
Subtotal (95% CI) 29 28 100.0 % 2.70 [ -2.49, 7.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
2 RV % predicted (end of study values)
Martinez-Garcia 2006 29 108 (10) 28 106 (29.2) 100.0 % 2.00 [ -9.41, 13.41 ]
Subtotal (95% CI) 29 28 100.0 % 2.00 [ -9.41, 13.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
3 TLC % predicted (end of study values)
Martinez-Garcia 2006 29 89.6 (10) 28 86.4 (10) 100.0 % 3.20 [ -1.99, 8.39 ]
Subtotal (95% CI) 29 28 100.0 % 3.20 [ -1.99, 8.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Chi2 = 0.04, df = 2 (P = 0.98), I2 =0.0%
-20 -10 0 10 20
Favours ICS Favours placebo
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Analysis 1.3. Comparison 1 Stable state bronchiectasis (6 months or less), Outcome 3 Clinical severity
indices.
Review: Inhaled corticosteroids for bronchiectasis
Comparison: 1 Stable state bronchiectasis (6 months or less)
Outcome: 3 Clinical severity indices
Study or subgroup
Inhaled
Corticos-
teroids Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Number of participants with regular wheeze (combined)
Martinez-Garcia 2006 18/58 9/28 0.95 [ 0.36, 2.50 ]
2 Number of participants without sputum reduction of > 50% (combined)
Martinez-Garcia 2006 33/58 25/28 0.16 [ 0.04, 0.58 ]
3 Number of participants with no improvement in dyspnoea score > 1 (min important difference) (1000F)
Martinez-Garcia 2006 10/29 18/28 0.29 [ 0.10, 0.87 ]
4 Number of participants with no clinically significant improvement in HRQoL
Martinez-Garcia 2006 33/58 26/28 0.10 [ 0.02, 0.47 ]
0.01 0.1 1 10 100
Favours ICS Favours placebo
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Analysis 1.4. Comparison 1 Stable state bronchiectasis (6 months or less), Outcome 4 Exacerbations.
Review: Inhaled corticosteroids for bronchiectasis
Comparison: 1 Stable state bronchiectasis (6 months or less)
Outcome: 4 Exacerbations
Study or subgroup
Inhaled
Corticos-
teroids Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Average number of exacerbations per participant
Hernando 2012 37 0.68 (0.81) 33 0.97 (1.16) 68.7 % -0.29 [ -0.76, 0.18 ]
Martinez-Garcia 2006 29 1.4 (1.3) 28 1.31 (1.4) 31.3 % 0.09 [ -0.61, 0.79 ]
Total (95% CI) 66 61 100.0 % -0.17 [ -0.56, 0.22 ]
Heterogeneity: Chi2 = 0.77, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours ICS Favours placebo
Analysis 1.5. Comparison 1 Stable state bronchiectasis (6 months or less), Outcome 5 Sputum and
biomarkers characteristics.
Review: Inhaled corticosteroids for bronchiectasis
Comparison: 1 Stable state bronchiectasis (6 months or less)
Outcome: 5 Sputum and biomarkers characteristics
Study or subgroup
Inhaled
Corticos-
teroids Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sputum volume or weight (per day)
Martinez-Garcia 2006 29 12.4 (10) 28 20.7 (20) -8.30 [ -16.55, -0.05 ]
-10 -5 0 5 10
Favours ICS Favours placebo
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Analysis 1.6. Comparison 1 Stable state bronchiectasis (6 months or less), Outcome 6 Pseudomonas
aeruginosa colonisation.
Review: Inhaled corticosteroids for bronchiectasis
Comparison: 1 Stable state bronchiectasis (6 months or less)
Outcome: 6 Pseudomonas aeruginosa colonisation
Study or subgroup
Inhaled
Corticos-
teroids Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hernando 2012 21/37 20/33 62.6 % 0.85 [ 0.33, 2.22 ]
Martinez-Garcia 2006 11/58 5/28 37.4 % 1.08 [ 0.33, 3.46 ]
Total (95% CI) 95 61 100.0 % 0.94 [ 0.45, 1.96 ]
Total events: 32 (Inhaled Corticosteroids), 25 (Placebo)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 1.7. Comparison 1 Stable state bronchiectasis (6 months or less), Outcome 7 St George HRQoL
(end of study minus baseline).
Review: Inhaled corticosteroids for bronchiectasis
Comparison: 1 Stable state bronchiectasis (6 months or less)
Outcome: 7 St George HRQoL (end of study minus baseline)
Study or subgroup
Inhaled
Corticos-
teroids Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Total score
Hernando 2012 37 0.56 (7.91) 33 3.78 (12.36) 82.0 % -3.22 [ -8.15, 1.71 ]
Martinez-Garcia 2006 29 -5 (19.85) 28 0 (20.7) 18.0 % -5.00 [ -15.53, 5.53 ]
Subtotal (95% CI) 66 61 100.0 % -3.54 [ -8.00, 0.92 ]
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.55 (P = 0.12)
2 Symptom score
Hernando 2012 37 1.9 (13.07) 33 4.5 (15.39) 70.9 % -2.60 [ -9.33, 4.13 ]
Martinez-Garcia 2006 29 -10 (20.3) 28 0 (20.2) 29.1 % -10.00 [ -20.52, 0.52 ]
Subtotal (95% CI) 66 61 100.0 % -4.75 [ -10.42, 0.92 ]
Heterogeneity: Chi2 = 1.35, df = 1 (P = 0.25); I2 =26%
Test for overall effect: Z = 1.64 (P = 0.10)
3 Activity score
Hernando 2012 37 2.48 (9.76) 33 8.01 (19.86) 68.8 % -5.53 [ -13.00, 1.94 ]
Martinez-Garcia 2006 29 -6.1 (20.3) 28 1.6 (22.37) 31.2 % -7.70 [ -18.80, 3.40 ]
Subtotal (95% CI) 66 61 100.0 % -6.21 [ -12.40, -0.01 ]
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.96 (P = 0.050)
4 Impact score
Hernando 2012 37 -0.82 (10.08) 33 2.81 (13.81) 100.0 % -3.63 [ -9.35, 2.09 ]
Subtotal (95% CI) 37 33 100.0 % -3.63 [ -9.35, 2.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.21)
Test for subgroup differences: Chi2 = 0.55, df = 3 (P = 0.91), I2 =0.0%
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Analysis 2.1. Comparison 2 Stable state (> 6 months), Outcome 1 Lung function indices.
Review: Inhaled corticosteroids for bronchiectasis
Comparison: 2 Stable state (> 6 months)
Outcome: 1 Lung function indices
Study or subgroup
Inhaled
corticos-
teroids Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 FEV1% predicted (end study minus baseline values)
Tsang 2005 43 0.3 (42.6) 43 0 (41.3) 0.30 [ -17.43, 18.03 ]
2 FVC % predicted (end study minus baseline values)
Tsang 2005 43 0 (32.84) 43 0.9 (31.93) -0.90 [ -14.59, 12.79 ]
-50 -25 0 25 50
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Analysis 2.2. Comparison 2 Stable state (> 6 months), Outcome 2 Exacerbations.
Review: Inhaled corticosteroids for bronchiectasis
Comparison: 2 Stable state (> 6 months)
Outcome: 2 Exacerbations
Study or subgroup
Inhaled
Corticos-
teroids Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Number of participants improved
Tsang 2005 21/43 27/43 0.57 [ 0.24, 1.34 ]
0.05 0.2 1 5 20
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Analysis 2.3. Comparison 2 Stable state (> 6 months), Outcome 3 Sputum and biomarker characteristics.
Review: Inhaled corticosteroids for bronchiectasis
Comparison: 2 Stable state (> 6 months)
Outcome: 3 Sputum and biomarker characteristics
Study or subgroup
Inhaled
corticos-
teroids Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sputum purulence score
Tsang 2005 43 5.7 (2.7) 43 5.5 (2.7) 0.20 [ -0.94, 1.34 ]
-2 -1 0 1 2
Favours placebo Favours ICS
A D D I T I O N A L T A B L E S
Table 1. Summary of included studies characteristics
Study ID Intervention Control Duration of intervention
Elborn 1992 Beclomethasone dipropionate 750
µg twice daily by MDI
Placebo 6 weeks
Hernando 2012 Budesonide 400 µg twice daily Placebo 6 months
Joshi 2004 Beclomethasone 800 µg per day
over 2 doses
Placebo 4 weeks
Martinez-Garcia 2006 Fluticasone 500 µg twice daily by
MDI or 250 µg fluticasone twice
daily
No treatment 6 months
Tsang 1998 Fluticasone 500 µg twice daily by
accuhaler
Placebo 4 weeks
Tsang 2004 Fluticasone 500 µg twice daily by
accuhaler
Placebo 52 weeks
Tsang 2005 Fluticasone 500 µg twice daily by
accuhaler
Placebo 52 weeks
MDI: metered dose inhaler
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A P P E N D I C E S
Appendix 1. Database search strategies
Database Search
Airways Register (searched through the
Cochrane Register of Studies)
steroid* or corticosteroid* or glucocorti-
coid* or beclomet* or budesonide or fluti-
casone OR ciclesonide or triamcinolone or
flunisolide
CENTRAL and MEDLINE (Ovid) strat-
egy
(MEDLINE search combined with RCT
search filter)
#1 MeSH descriptor Bronchiectasis ex-
plode all trees
#2 bronchiect*
#3 (#1 OR #2)
#4 MeSH descriptor Adrenal Cortex Hor-
mones explode all trees
#5 steroid*
#6 corticosteroid*
#7 glucocorticoid*
#8 beclomet*
#9 0fluticasone
#11 ciclesonide
#12 flunisolide
#13 triamcinolone
#14 (#4 OR #5 OR #6 OR #7 OR #8 OR
#9 OR #10 OR #11 OR #12 OR #12)
#15 (#3 AND #14)
Embase (Ovid) strategy
(combined with RCT search filter)
#1 Emtree descriptor Bronchiectasis ex-
plode all trees
#2 bronchiect*
#3 (#1 OR #2)
#4 Emtree descriptor Corticosteroid ex-
plode all trees
#5 steroid*
#6 corticosteroid*
#7 glucocorticoid*
#8 beclomet*
#9 budesonide
#10 fluticasone
#11 ciclesonide
#12 flunisolide
#13 triamcinolone
#14 (#4 OR #5 OR #6 OR #7 OR #8 OR
#9 OR #10 OR #11 OR #12 OR #12)
#15 (#3 AND #14)
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Appendix 2. Search strategy to identify relevant trials from ClinicalTrials.gov andWHO trials portal
“inhaled corticosteroid” AND “bronchiectasis” AND “clinical trials”
WH A T ’ S N E W
Last assessed as up-to-date: 30 June 2017.
Date Event Description
30 June 2017 New search has been performed Literature search run.
30 June 2017 New citation required but conclusions have not changed One new study included in the review. Addition of au-
thor. Review updated to reflect current Cochrane meth-
ods including addition of ’Summary of findings’ table and
PRISMA flow chart. See Differences between protocol
and review.
H I S T O R Y
Protocol first published: Issue 2, 1997
Review first published: Issue 2, 1999
Date Event Description
15 August 2008 New citation required and conclusions have changed Aug 2008: new author team, protocol changed and
previous included studies data amended, new studies
added, conclusions changed
5 May 2008 Amended Converted to new review format.
10 September 2007 New search has been performed New literature search performed.
C O N T R I B U T I O N S O F A U T H O R S
The protocol was written by NK and AC based on previous protocols on cough in children. For the review update: NK and AC
performed selection of articles from the search, data extraction, data analysis and writing of the review. HP prepared the manuscript.
SB and JK reviewed the manuscript.
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D E C L A R A T I O N S O F I N T E R E S T
Nitin Kapur: none known.
Helen Petsky: none known.
Scott Bell: has received travel and accommodation support to attend investigator meetings (Vertex, Rempex), to participate in advisory
boards and to speak at sponsored Symposia. Speakers fees and support to participate in preparation of educational materials and in
advisory board have been paid to his Institution.
John Kolbe: has received funds of approximately NZ $500 from Novartis for lecture to GPs as part of an educational symposium. John
also received funds to attend investigator meetings from Aradigm, GSK, Insmed, and Corus.
Anne Chang: grant provided by GSK is unrelated to this topic.
S O U R C E S O F S U P P O R T
Internal sources
• Royal Children’s Hospital Foundation, Brisbane, Australia.
Salary support from the Foundation for the 2009 version of this review
External sources
• National Health and Medical Research Council, Australia.
AC’s Practitioner Fellowship and Project Grant
• Asthma Australia, Australia.
HP is supported through an Early Career Fellowship
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• In the original protocol, we defined ’long-term effect’ as that measured at more than 12 months duration. We changed this to
more than six months duration in the first review undertaken by the current group of review authors.
• We included data from the Martinez-Garcia 2006 study in the review, although the comparison between the untreated and the
inhaled corticosteroids (ICS) groups were not blinded. Also, for clinical severity assessment in the Martinez-Garcia 2006 study, we
used outcome variables of sputum reduction > 50% and dyspnoea score improvement > 1 posthoc, since these were the ones available
from the study.
• We moved lung function to a primary outcome.
• We included ’Summary of findings’ tables in the review.
• We added a study flow diagram.
• We specified the methods in more detail following the MECIR standards.
• We redrafted all sections under recommended headings.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Inhalation; Adrenal Cortex Hormones [∗administration & dosage]; Androstadienes [administration & dosage]; Anti-
Bacterial Agents [administration & dosage]; Beclomethasone [administration & dosage]; Bronchiectasis [∗drug therapy]; Fluticasone;
Randomized Controlled Trials as Topic; Respiratory Function Tests
MeSH check words
Adult; Humans
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